Skip to content
vaccines hero image
vaccines hero image

Vaccines

Vaccines contain antigenic substances capable of inducing immunity against an infective agent or toxin.

They are frequently administered prophylactically but are increasingly being researched and developed in a therapeutic context (eg cancer vaccines which are designed to equip a patient’s immune system to treat an existing cancer).

While the global market for vaccines is less than 3% of the total pharmaceuticals market, World Health Organization research suggests that over the next few years, the vaccine market will enjoy a growth rate of 10% to 15% per year versus the 5% to 7% seen in the overall market.

To take a share of this expanding market, companies must navigate a number of challenges. The assessment, licensing and control of vaccines (which are biological medicinal products) occurs in an environment of rapid innovation and complex quality concerns. Our deep experience of vaccines, combined with the fact that our team includes lawyers with degrees in relevant scientific areas (molecular biology, biochemistry, genetics etc), enables us to quickly grasp evolving issues and technical concepts and provide nuanced and tailored advice.

We are trusted by many of the world’s leading vaccine companies to help them navigate all stages of the vaccine lifecycle.


News and insights

test tubes and dropper

News: 09 February 2024

Allen & Overy conseille le groupe Sartorius sur son augmentation de capital d'un montant de 1,4 milliard d'euros

Frankfurt am Main - Allen & Overy a conseillé le groupe Sartorius sur son augmentation de capital d'un montant total de 1,4 milliard d'euros. La transaction comprenait le placement de 613 497 actions…

Lire la suite
Testing tube

Publications: 21 July 2023

Nouveau rebondissement dans l’affaire Illumina/GRAIL : Acquéreur et Cible sanctionnés pour gun jumping

Le 12 juillet 2023, la Commission européenne (la Commission) a annoncé avoir sanctionné Illumina à hauteur de 432 millions d’euros ainsi que GRAIL, la cible, à une amende symbolique de 1 000 euros…

Lire la suite

Publications: 21 July 2022

Acquisition de GRAIL par Illumina : le Tribunal de l’UE donne son feu vert à la nouvelle politique de renvoi de la Commission

Le Tribunal de l’UE a rendu un arrêt historique ce 13 juillet 2022 en confirmant la décision de la Commission européenne (la Commission) acceptant une demande de renvoi émanant de la France (et de…

Lire la suite